These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 33054533)

  • 1. Optical coherence tomography outcomes from SPRINT-MS, a multicenter, randomized, double-blind trial of ibudilast in progressive multiple sclerosis.
    Bermel RA; Fedler JK; Kaiser P; Novalis C; Schneebaum J; Klingner EA; Williams D; Yankey JW; Ecklund DJ; Chase M; Naismith RT; Klawiter EC; Goodman AD; Coffey CS; Fox RJ
    Mult Scler; 2021 Aug; 27(9):1384-1390. PubMed ID: 33054533
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of Ibudilast on Retinal Atrophy in Progressive Multiple Sclerosis Subtypes: Post Hoc Analyses of the SPRINT-MS Trial.
    Ehrhardt H; Lambe J; Moussa H; Vasileiou ES; Kalaitzidis G; Murphy OC; Filippatou AG; Pellegrini N; Douglas M; Davis S; Nagy N; Quiroga A; Hu C; Zambriczki Lee A; Duval A; Fitzgerald KC; Prince JL; Calabresi PA; Sotirchos ES; Bermel R; Saidha S
    Neurology; 2023 Sep; 101(10):e1014-e1024. PubMed ID: 37460235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis.
    Fox RJ; Coffey CS; Conwit R; Cudkowicz ME; Gleason T; Goodman A; Klawiter EC; Matsuda K; McGovern M; Naismith RT; Ashokkumar A; Barnes J; Ecklund D; Klingner E; Koepp M; Long JD; Natarajan S; Thornell B; Yankey J; Bermel RA; Debbins JP; Huang X; Jagodnik P; Lowe MJ; Nakamura K; Narayanan S; Sakaie KE; Thoomukuntla B; Zhou X; Krieger S; Alvarez E; Apperson M; Bashir K; Cohen BA; Coyle PK; Delgado S; Dewitt LD; Flores A; Giesser BS; Goldman MD; Jubelt B; Lava N; Lynch SG; Moses H; Ontaneda D; Perumal JS; Racke M; Repovic P; Riley CS; Severson C; Shinnar S; Suski V; Weinstock-Guttman B; Yadav V; Zabeti A;
    N Engl J Med; 2018 Aug; 379(9):846-855. PubMed ID: 30157388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, rationale, and baseline characteristics of the randomized double-blind phase II clinical trial of ibudilast in progressive multiple sclerosis.
    Fox RJ; Coffey CS; Cudkowicz ME; Gleason T; Goodman A; Klawiter EC; Matsuda K; McGovern M; Conwit R; Naismith R; Ashokkumar A; Bermel R; Ecklund D; Koepp M; Long J; Natarajan S; Ramachandran S; Skaramagas T; Thornell B; Yankey J; Agius M; Bashir K; Cohen B; Coyle P; Delgado S; Dewitt D; Flores A; Giesser B; Goldman M; Jubelt B; Lava N; Lynch S; Miravalle A; Moses H; Ontaneda D; Perumal J; Racke M; Repovic P; Riley C; Severson C; Shinnar S; Suski V; Weinstock-Gutman B; Yadav V; Zabeti A
    Contemp Clin Trials; 2016 Sep; 50():166-77. PubMed ID: 27521810
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of ibudilast on thalamic magnetization transfer ratio and volume in progressive multiple sclerosis.
    Nakamura K; Zheng Y; Mahajan KR; Cohen JA; Fox RJ; Ontaneda D
    Mult Scler; 2023 Sep; 29(10):1257-1265. PubMed ID: 37537928
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ibudilast reduces slowly enlarging lesions in progressive multiple sclerosis.
    Nakamura K; Thoomukuntla B; Bena J; Cohen JA; Fox RJ; Ontaneda D
    Mult Scler; 2024 Mar; 30(3):369-380. PubMed ID: 38286755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of ibudilast on thalamic volume in progressive multiple sclerosis.
    Nicholson S; Russo AW; Brewer K; Bien H; Tobyne SM; Eloyan A; Klawiter EC
    Mult Scler; 2023 Dec; 29(14):1819-1830. PubMed ID: 37947294
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum macrophage migration inhibitory factor levels predict brain atrophy in people with primary progressive multiple sclerosis.
    Ladakis DC; Reyes-Mantilla MI; Gadani SP; Mace JW; Dominguez-Penuela SC; Appiah MJ; Smith MD; Bhargava P; Fox RJ; Saidha S; Calabresi PA
    Mult Scler; 2024 Jan; 30(1):35-43. PubMed ID: 37982154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ibudilast in relapsing-remitting multiple sclerosis: a neuroprotectant?
    Barkhof F; Hulst HE; Drulovic J; Uitdehaag BM; Matsuda K; Landin R;
    Neurology; 2010 Mar; 74(13):1033-40. PubMed ID: 20200338
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative diagnostic accuracy of ganglion cell-inner plexiform and retinal nerve fiber layer thickness measures by Cirrus and Spectralis optical coherence tomography in relapsing-remitting multiple sclerosis.
    González-López JJ; Rebolleda G; Leal M; Oblanca N; Muñoz-Negrete FJ; Costa-Frossard L; Alvarez-Cermeño JC
    Biomed Res Int; 2014; 2014():128517. PubMed ID: 25313352
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neurofilament light chain in a phase 2 clinical trial of ibudilast in progressive multiple sclerosis.
    Fox RJ; Raska P; Barro C; Karafa M; Konig V; Bermel RA; Chase M; Coffey CS; Goodman AD; Klawiter EC; Naismith RT; Kuhle J
    Mult Scler; 2021 Nov; 27(13):2014-2022. PubMed ID: 33635141
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optical coherence tomography in multiple sclerosis: A 3-year prospective multicenter study.
    Paul F; Calabresi PA; Barkhof F; Green AJ; Kardon R; Sastre-Garriga J; Schippling S; Vermersch P; Saidha S; Gerendas BS; Schmidt-Erfurth U; Agoropoulou C; Zhang Y; Seifer G; Petzold A
    Ann Clin Transl Neurol; 2021 Dec; 8(12):2235-2251. PubMed ID: 34792863
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Response to ibudilast treatment according to progressive multiple sclerosis disease phenotype.
    Goodman AD; Fedler JK; Yankey J; Klingner EA; Ecklund DJ; Goebel CV; Bermel RA; Chase M; Coffey CS; Klawiter EC; Naismith RT; Fox RJ;
    Ann Clin Transl Neurol; 2021 Jan; 8(1):111-118. PubMed ID: 33460301
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retinal Thickness Analysis in Progressive Multiple Sclerosis Patients Treated With Epigallocatechin Gallate: Optical Coherence Tomography Results From the SUPREMES Study.
    Klumbies K; Rust R; Dörr J; Konietschke F; Paul F; Bellmann-Strobl J; Brandt AU; Zimmermann HG
    Front Neurol; 2021; 12():615790. PubMed ID: 33995239
    [No Abstract]   [Full Text] [Related]  

  • 15. Predictors of retinal atrophy in multiple sclerosis: A longitudinal study using spectral domain optical coherence tomography with segmentation analysis.
    Behbehani R; Adnan H; Al-Hassan AA; Al-Salahat A; Alroughani R
    Mult Scler Relat Disord; 2018 Apr; 21():56-62. PubMed ID: 29459346
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of Ibudilast on MRI Measures in the Phase 2 SPRINT-MS Study.
    Naismith RT; Bermel RA; Coffey CS; Goodman AD; Fedler J; Kearney M; Klawiter EC; Nakamura K; Narayanan S; Goebel C; Yankey J; Klingner E; Fox RJ;
    Neurology; 2021 Jan; 96(4):e491-e500. PubMed ID: 33268562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Papillomacular bundle and inner retinal thicknesses correlate with visual acuity in nonarteritic anterior ischemic optic neuropathy.
    Rebolleda G; Sánchez-Sánchez C; González-López JJ; Contreras I; Muñoz-Negrete FJ
    Invest Ophthalmol Vis Sci; 2015 Jan; 56(2):682-92. PubMed ID: 25587057
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Visual dysfunction in multiple sclerosis correlates better with optical coherence tomography derived estimates of macular ganglion cell layer thickness than peripapillary retinal nerve fiber layer thickness.
    Saidha S; Syc SB; Durbin MK; Eckstein C; Oakley JD; Meyer SA; Conger A; Frohman TC; Newsome S; Ratchford JN; Frohman EM; Calabresi PA
    Mult Scler; 2011 Dec; 17(12):1449-63. PubMed ID: 21865411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optic Disc and Macular Imaging in Blind Eyes from Non-glaucomatous Optic Neuropathy: A Study with Spectral-domain Optical Coherence Tomography.
    Hansapinyo L; Cheng AC; Chan NC; Chan CK
    Neuroophthalmology; 2017 Feb; 41(1):1-6. PubMed ID: 28228830
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retinal thickness measured with optical coherence tomography and risk of disability worsening in multiple sclerosis: a cohort study.
    Martinez-Lapiscina EH; Arnow S; Wilson JA; Saidha S; Preiningerova JL; Oberwahrenbrock T; Brandt AU; Pablo LE; Guerrieri S; Gonzalez I; Outteryck O; Mueller AK; Albrecht P; Chan W; Lukas S; Balk LJ; Fraser C; Frederiksen JL; Resto J; Frohman T; Cordano C; Zubizarreta I; Andorra M; Sanchez-Dalmau B; Saiz A; Bermel R; Klistorner A; Petzold A; Schippling S; Costello F; Aktas O; Vermersch P; Oreja-Guevara C; Comi G; Leocani L; Garcia-Martin E; Paul F; Havrdova E; Frohman E; Balcer LJ; Green AJ; Calabresi PA; Villoslada P;
    Lancet Neurol; 2016 May; 15(6):574-84. PubMed ID: 27011339
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.